Major Depressive Disorder (MDD), colloquially known as depression, has plagued millions of people over the course of time, and research suggests that between 30-35% of depression cases meet the criteria to be deemed treatment-resistant depression (TRD). Despite the relatively low figure representing treatment resistance, a lot of the population experiencing depression maintains a low response rate to treatment in general. The established difficulty in treating so many cases of depression has created room for masses of research to be done regarding effective second-line remedies, and recently, the FDA has allowed depression treatment and research with drugs such as ketamine. 

Major Depressive Disorder (MDD), colloquially known as depression, has plagued millions of people over the course of time, and research suggests that between 30-35% of depression cases meet the criteria to be deemed treatment-resistant depression (TRD). Despite the relatively low figure representing treatment resistance, a lot of the population experiencing depression maintains a low response rate to treatment in general. The established difficulty in treating so many cases of depression has created room for masses of research to be done regarding effective second-line remedies, and recently, the FDA has allowed depression treatment and research with drugs such as ketamine.